EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.
Toosi BM, El Zawily A, Truitt L, Shannon M, Allonby O, Babu M, DeCoteau J, Mousseau D, Ali M, Freywald T, et al. Oncogene. 2018 Jul; 37(30):4073-4093. Epub 2018 Apr 27.